These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 28322598)

  • 21. Entry inhibitors and their use in the treatment of HIV-1 infection.
    Haqqani AA; Tilton JC
    Antiviral Res; 2013 May; 98(2):158-70. PubMed ID: 23541872
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Function-oriented development of CXCR4 antagonists as selective human immunodeficiency virus (HIV)-1 entry inhibitors.
    Wu CH; Wang CJ; Chang CP; Cheng YC; Song JS; Jan JJ; Chou MC; Ke YY; Ma J; Wong YC; Hsieh TC; Tien YC; Gullen EA; Lo CF; Cheng CY; Liu YW; Sadani AA; Tsai CH; Hsieh HP; Tsou LK; Shia KS
    J Med Chem; 2015 Feb; 58(3):1452-65. PubMed ID: 25584630
    [TBL] [Abstract][Full Text] [Related]  

  • 23. N-substituted pyrrole derivatives as novel human immunodeficiency virus type 1 entry inhibitors that interfere with the gp41 six-helix bundle formation and block virus fusion.
    Jiang S; Lu H; Liu S; Zhao Q; He Y; Debnath AK
    Antimicrob Agents Chemother; 2004 Nov; 48(11):4349-59. PubMed ID: 15504864
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Functional impact of HIV coreceptor-binding site mutations.
    Biscone MJ; Miamidian JL; Muchiri JM; Baik SS; Lee FH; Doms RW; Reeves JD
    Virology; 2006 Jul; 351(1):226-36. PubMed ID: 16631222
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mapping resistance to the CCR5 co-receptor antagonist vicriviroc using heterologous chimeric HIV-1 envelope genes reveals key determinants in the C2-V5 domain of gp120.
    Ogert RA; Wojcik L; Buontempo C; Ba L; Buontempo P; Ralston R; Strizki J; Howe JA
    Virology; 2008 Apr; 373(2):387-99. PubMed ID: 18190945
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Virtual screening of small molecular HIV-1 entry inhibitor NC-2 targeting gp120 and its action mechanism].
    Duan H; Wang Y; Song D; Chen Z; Qiu J; Lu L; Jiang S; Liu S; Tan S
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Jun; 33(6):826-31. PubMed ID: 23803191
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amino acid derivatives of the (-) enantiomer of gossypol are effective fusion inhibitors of human immunodeficiency virus type 1.
    An T; Ouyang W; Pan W; Guo D; Li J; Li L; Chen G; Yang J; Wu S; Tien P
    Antiviral Res; 2012 Jun; 94(3):276-87. PubMed ID: 22426469
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.
    Castagna A; Biswas P; Beretta A; Lazzarin A
    Drugs; 2005; 65(7):879-904. PubMed ID: 15892586
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Tat-based cell-cell fusion method for screening HIV-1 fusion inhibitors].
    Wang X; Yang Y; Shen S; Wang X; Feng T; Hu Q; Zeng Y
    Sheng Wu Gong Cheng Xue Bao; 2018 Mar; 34(3):429-439. PubMed ID: 29577693
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lattice engineering enables definition of molecular features allowing for potent small-molecule inhibition of HIV-1 entry.
    Lai YT; Wang T; O'Dell S; Louder MK; Schön A; Cheung CSF; Chuang GY; Druz A; Lin B; McKee K; Peng D; Yang Y; Zhang B; Herschhorn A; Sodroski J; Bailer RT; Doria-Rose NA; Mascola JR; Langley DR; Kwong PD
    Nat Commun; 2019 Jan; 10(1):47. PubMed ID: 30604750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Frequency and Env determinants of HIV-1 subtype C strains from antiretroviral therapy-naive subjects that display incomplete inhibition by maraviroc.
    Borm K; Jakobsen MR; Cashin K; Flynn JK; Ellenberg P; Ostergaard L; Lee B; Churchill MJ; Roche M; Gorry PR
    Retrovirology; 2016 Nov; 13(1):74. PubMed ID: 27809912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals.
    Irlbeck DM; Amrine-Madsen H; Kitrinos KM; Labranche CC; Demarest JF
    AIDS; 2008 Jul; 22(12):1425-31. PubMed ID: 18614865
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HIV-1 entry inhibition by small-molecule CCR5 antagonists: a combined molecular modeling and mutant study using a high-throughput assay.
    Labrecque J; Metz M; Lau G; Darkes MC; Wong RS; Bogucki D; Carpenter B; Chen G; Li T; Nan S; Schols D; Bridger GJ; Fricker SP; Skerlj RT
    Virology; 2011 May; 413(2):231-43. PubMed ID: 21388649
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Functional Mimetics of the HIV-1 CCR5 Co-Receptor Displayed on the Surface of Magnetic Liposomes.
    Kuzmina A; Vaknin K; Gdalevsky G; Vyazmensky M; Marks RS; Taube R; Engel S
    PLoS One; 2015; 10(12):e0144043. PubMed ID: 26629902
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The relative activity of "function sparing" HIV-1 entry inhibitors on viral entry and CCR5 internalization: is allosteric functional selectivity a valuable therapeutic property?
    Muniz-Medina VM; Jones S; Maglich JM; Galardi C; Hollingsworth RE; Kazmierski WM; Ferris RG; Edelstein MP; Chiswell KE; Kenakin TP
    Mol Pharmacol; 2009 Mar; 75(3):490-501. PubMed ID: 19064629
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel small-molecule inhibitor of HIV-1 entry.
    Heredia A; Latinovic OS; Barbault F; de Leeuw EP
    Drug Des Devel Ther; 2015; 9():5469-78. PubMed ID: 26491257
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gold nanoparticles as an HIV entry inhibitor.
    Vijayakumar S; Ganesan S
    Curr HIV Res; 2012 Dec; 10(8):643-6. PubMed ID: 22954307
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discoveries and developments of CXCR4-targeted HIV-1 entry inhibitors.
    Zhang C; Zhu R; Cao Q; Yang X; Huang Z; An J
    Exp Biol Med (Maywood); 2020 Mar; 245(5):477-485. PubMed ID: 32019336
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biased small-molecule ligands for selective inhibition of HIV-1 cell entry via CCR5.
    Berg C; Spiess K; Lüttichau HR; Rosenkilde MM
    Pharmacol Res Perspect; 2016 Dec; 4(6):e00262. PubMed ID: 28097000
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Envelope proteins as antiviral drug target.
    Verma J; Subbarao N; Rajala MS
    J Drug Target; 2020 Dec; 28(10):1046-1052. PubMed ID: 32643453
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.